Experience

Davis Polk is advising Arch Coal, Inc. (“Arch”) in connection with its restructuring under chapter 11 of the Bankruptcy Code, a $275 million debtor-in-possession (DIP) financing facility…

Davis Polk advised the joint book-running managers in connection with an $86.2 million SEC-registered follow-on common stock offering of 8,625,000 shares of common stock for Ardelyx, Inc…

Davis Polk advised the joint book-running managers of an SEC-registered offering by Black Hills Corporation of $250 million aggregate principal amount of its 2.500% notes due 2019 and $300…

Davis Polk advised the underwriters in connection with an SEC-registered Schedule B debt offering by The Korea Development Bank of $500 million aggregate principal amount of its 2.5% notes…

Davis Polk advised the joint book-running managers in connection with a $66.1 million SEC-registered common stock offering of 2,875,000 shares of common stock of Adamas Pharmaceuticals, Inc…

Davis Polk advised the underwriters in connection with the SEC-registered offering of 4,166,167 shares of common stock of Cempra, Inc. The net proceeds to Cempra were approximately $93.7…

Davis Polk is advising I Squared Capital in connection with its acquisition of Lincoln Clean Energy through its ISQ Global Infrastructure Fund. The transaction includes an operating solar…

Davis Polk is advising Affymetrix, Inc. in connection with its sale to Thermo Fisher Scientific Inc. for a total equity value of approximately $1.3 billion. The transaction, which is…

Davis Polk is advising Charles River Laboratories International, Inc. on its acquisition of WIL Research for approximately $585 million. The transaction, which is expected to close early in…

Davis Polk is advising China Cinda Asset Management Co., Ltd. (“China Cinda”) in connection with a proposed strategic investment by Sino Biopharmaceutical Limited. Pursuant to terms of the…